Amgen Projects Neulasta Sales Driven By Prescribing Growth, Not Switches
Executive Summary
Amgen expects Neulasta (pegfilgrastim) 2004 sales to be driven by an increase in the patient population and changes in prescribing patterns
You may also be interested in...
Amgen Enbrel Will Participate In Medicare Part B Replacement
Amgen's Enbrel will be included in Medicare's demonstration program for self-injected biologics
Neulasta First-Cycle Use Will Be Supported By ASCO Guidelines, Amgen Says
Revised ASCO guidelines will support first-cycle prophylactic use of Neulasta, Amgen Senior VP-Development Beth Seidenberg, MD, said
Amgen Enbrel Will Participate In Medicare Part B Replacement
Amgen's Enbrel will be included in Medicare's demonstration program for self-injected biologics